....Nothing major, but certainly worth a mention.EXEL's got #364 for CABO in RCC & #372 in mrRCC for Foretinib. Here's the link...Barring a surprise, these may be all we really hear out of SF this week. Fingers crossed...If I've missed something, pls post a corrective note...http://gucasymposium.org/MeetingProgram/GeneralPosterSessionE.aspxGLTA
Bump as well,
http://www.ncbi.nlm.nih.gov/pubmed/21551255http://med.stanford.edu/clinicaltrials/detail.do?studyId=928 Looking forward to the newest info. coming this week.
...Also #355 for Foretinib...